Scientific article

Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation

Published inTransplant infectious disease, vol. 11, no. 1, p. 33-39
Publication date2009

Hepatitis C virus (HCV) infection invariably recurs after liver transplantation (LT), leading to significant morbidity and mortality. Although the combination of pegylated interferon-alpha (IFN-alpha)/ribavirin is the preferred treatment for these patients, the optimal schedule remains undetermined. In an uncontrolled trial, 19 patients with HCV infection recurring after LT received pegylated IFN-alpha(2a), 180 mug weekly, and ribavirin, 10 mg/kg body weight daily, for 48 weeks. The proportion of patients with undetectable HCV RNA in their serum after 12 weeks of treatment was 53%. Five patients (26%) dropped out of the study due to intolerance (in 2 cases), depression (in 1), or infectious complications (in 2). A sustained virological response (SVR), defined as undetectable serum HCV RNA 24 weeks after the end of treatment, was observed in 9/19 patients (47%). SVR was associated with an early virological response after 12 weeks of therapy (P<0.001) and a treatment duration >80% (P=0.02), but not with baseline HCV RNA level or a cumulative dose of pegylated IFN-alpha(2a) or ribavirin >80% of the scheduled dose. All 4 patients with genotype 2 or 3 reached SVR, as compared with 33% of patients with genotype 1 or 4 (P=0.03). A 48-week course of pegylated IFN-alpha(2a)/ribavirin therapy is effective in patients with recurrent HCV infection after LT.

  • Adult
  • Aged
  • Antiviral Agents/*administration & dosage/therapeutic use
  • Female
  • Graft Rejection
  • Graft Survival
  • Hepacivirus/drug effects
  • Hepatitis C/*drug therapy/mortality
  • Humans
  • Interferon-alpha/administration & dosage/*therapeutic use
  • Liver Transplantation/*adverse effects
  • Male
  • Middle Aged
  • Polyethylene Glycols/administration & dosage/*therapeutic use
  • Recombinant Proteins
  • Recurrence
  • Ribavirin/administration & dosage/*therapeutic use
  • Survival Rate
  • Treatment Outcome
Citation (ISO format)
DINGES, S. et al. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation. In: Transplant infectious disease, 2009, vol. 11, n° 1, p. 33–39. doi: 10.1111/j.1399-3062.2008.00359.x
Main files (1)
ISSN of the journal1398-2273

Technical informations

Creation04/23/2012 1:23:24 PM
First validation04/23/2012 1:23:24 PM
Update time03/14/2023 5:24:45 PM
Status update03/14/2023 5:24:44 PM
Last indexation02/12/2024 7:57:51 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack